Stock data
| Market cap. | US$181.9m |
| Last close | US$12.51 |
| High / Low (52 weeks) | US$18.6 / US$9.2 |
| Stock market listing | NASDAQ |
| Forecast net cash (US$m) | 90.3 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 2.2059 | (13.7241) | (19.1338) |
| Relative * | 5.6598 | (11.5594) | (18.8487) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 13.6 | (10.7) | (11.5) | (164.2) | N/A | N/A |
| 2011A | 5.5 | (22.3) | (14.7) | (150.8) | N/A | N/A |
| 2012E | 9.1 | (19.7) | (19.4) | (148.2) | N/A | N/A |
| 2013E | 9.1 | (21.0) | (20.8) | (142.1) | N/A | N/A |
Last updated on 19/04/2012
Latest research
Trial changes and cash
Update | Pharmaceutical & Healthcare | 03/04/2012
Second string to bow
Update | Pharmaceutical & Healthcare | 13/02/2012
Remember custirsen
Outlook | Pharmaceutical & Healthcare | 07/11/2011
Investment summary
OncoGenex has two promising antisense therapies in clinical trials, both with the potential to treat many cancers. Its lead product, custirsen, is in a pivotal Phase III trial, SYNERGY, in castration resistant prostate cancer (CRPC); this study should report data in Q413. Two other Phase III trials should start in 2012, one in non-small cell lung cancer and a second one in CRPC (this will replace the SATURN trial, which is being terminated). Custirsen is partnered with Teva and increased median overall survival by 41% to 23.8 months in a Phase II study in CRPC. Its second clinical drug OGX-427 demonstrated promising anti-tumour activity in a Phase II in CRPC and Phase I in bladder cancer and was well tolerated. It had net cash of $64m at FY11 and has just raised $54m in equity.
Last updated on 23/04/2012
Industry outlook
There remains a significant unmet need for efficacious oncology products, in particular for those which do not impair a patient's quality of life. Both OncoGenex's products appear to be highly efficacious and have limited side effects.
Last updated on 23/04/2012
Key management
| Jack Goldstein, Chairman |
| Scott Cormack, CEO |
| Michelle Burris, CFO |
Company address
| 1522 217th Place SE Suite 100 Bothell 98021 United States (425) 686-1500 View website |
